Publications

5808 Results

Impact of primary (1º) tumor location on overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405

Authors
A Venook;D Niedzwiecki;F Innocenti;M Fruth;C Greene;B O'Neil;JE Shaw;B Polite;H Hochster;C Blanke;R Goldberg;R Schilsky;R Mayer;M Bertagnolli;H Lenz
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 3504); oral American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL),
Year
2016
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

A double blind randomization to letrozole or placebo for women previously diagnosed with primary breast cancer completing five years of adjuvant aromatase inhibitor either as initial therapy or after tamoxifen (including those in the MA.17R study)

Authors
P Goss;J Ingle;H Muss;J Gralow;K Gelmon;T Whelan;K Strasser-Weippl;S Rubin;K Sturtz;A Wolff;E Winer;C Hudis;A Stopeck;JT Beck;J Salmon Kaur;K Whelan;D Tu;W Parulekar
Journal / Conference
J Clin Oncol 34 (suppl; abstr LBA1); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral
Year
2016
Research Committee(s)
Breast

The SWOG Cancer Survivor Project to Develop a Cancer Survivor Web Portal for an Individual Clinical Trial Summary

Authors
MA O'Rourke;E Lackey;K Anderson;A Gottlieb;R Krouse;C Fabian;J Klemp
Journal / Conference
Biennial Survivorship Research Conference (June 16-18, 2016, Washington, DC), poster session
Year
2016
Research Committee(s)
Cancer Survivorship

Patient reported outcomes from MA.17R: a randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 Years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer

Authors
J Lemieux;PE Goss;W Parulekar;J Ingle;K Pritchard;NJ Robert;H Muss;J Gralow;K Strasser-Weippl;MD Brundage;K Whelan;D Tu;T Whelan
Journal / Conference
Journal of Clinical Oncology 34 (suppl; abstr LBA506); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral plenary and press sessions
Year
2016
Research Committee(s)
Breast

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

Authors
P Ganz;R Cecchini;T Julian;R Margolese;J Costantino;J Vallow;K Albain;P Whitworth;M Cianfrocca;A Brufsky;H Gross;G Soori;J Hopkins;L Fehrenbacher;K Sturtz;T Wozniak;TE Seay;E Mamounas;N Wolmark
Journal / Conference
Lancet, Feb 27;387(10021):857-865
Year
2016
Research Committee(s)
Breast
PMID
PMID26686960
PMC
PMC4792658

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

Authors
R Margolese;R Cecchini;T Julian;P Ganz;J Costantino;L Vallow;K Albain;P Whitworth;M Cianfrocca;A Brufsky;H Gross;G Soori;J Hopkins;L Fehrenbacher;K Sturtz;T Wozniak;TE Seay;E Mamounas;N Womark
Journal / Conference
Lancet Feb 27;387(10021):849-856
Year
2016
Research Committee(s)
Breast
PMID
PMID26686957
PMC
PMC4792688

The 21-gene recurrence score and locoregional recurrence rates in patients with node-positive breast cancer treated on SWOG S8814

Authors
W Woodward;W Barlow;R Jagsi;T Buccholz;S Shak;F Baehner;C Yoshizawa;T Whelan;N Davidson;J Ingle;T King;P Ravdin;C Osborne;D Tripathy;R Livingston;J Gralow;G Hortobagyi;D Hayes;K Albain
Journal / Conference
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S146;oral; ASTRO Annal Meeting (September 25 - 28, 2016, Boston, MA)
Year
2016
Research Committee(s)
Breast
Study Number(s)
SWOG-8814

Effect of measurable ("minimal") residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

Authors
M Othus;B Wood;D Stirewalt;E Estey;S Petersdorf;F Appelbaum;H Erba;R Walter
Journal / Conference
Leukemia Oct;30(10):2080-2083; 2016 May 2 [Epub ahead of print]
Year
2016
Research Committee(s)
Leukemia
PMID
PMID27133827
PMC
PMC5053842
Study Number(s)
S0106

Adjuvant therapy for high-risk kidney cancer: ECOG-ACRIN E2805

Authors
NB Haas;J Manola;R Uzzo;K Flaherty;C Wood;C Kane;M Jewett;J Dutcher;MB Atkins;M Pins;G Wilding;D Cella;L Wagner;S Matin;T Kuzel;W Sexton;Y Wong;T Choueiri;R Pili;R Puzanov;M Kohli;W Stadler;M Carducci;R Coomes;R Dipaola
Journal / Conference
Lancet May 14;387(10032):2008-2016; 2016 Mar 8 [Epub ahead of print]
Year
2016
Research Committee(s)
Genitourinary
PMID
PMID26969090
PMC
PMC4878938
Study Number(s)
CTSU/E2805

SWOG S0800 (NCI CDR0000636131):Addition of bevacizumab to neoadjuvant nab-paclitaxel with dose–dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer

Authors
Z Nahleh;W Barlow;D Hayes;A Schott;J Gralow;E Perez;W Sikov;S Chennuru;H Mirshahidi;S Corso;D Lew;L Pusztai;R Livingston;G Hortobagyi
Journal / Conference
Breast Cancer Research and Treatment Aug;158(3):485-495; 2016 Jul 8 [Epub ahead of print]
Year
2016
Research Committee(s)
Breast
PMID
PMID27393622
PMC
PMC4963434
Study Number(s)
S0800